Delineate vs Armilla AI
Side-by-side comparison of AI visibility scores, market position, and capabilities
US AI clinical trial design and systematic review automation extracting data from papers and figures at 15x industry speed for two top-10 pharma partners; competing with Elsevier Reaxys for biopharma evidence synthesis that reduces study times from months to weeks.
About
Delineate is a United States-based AI clinical trial design and biomedical data extraction company — providing pharmaceutical companies, academic research teams, and contract research organizations (CROs) with AI-powered systematic review automation that accelerates the data extraction and evidence synthesis workflows critical for designing better, faster clinical trials in the $10 billion clinical trial design and data services market. Partnered with two top-10 global pharmaceutical companies, Delineate has performed some of the largest systematic-review studies ever conducted in drug development, delivering 15x more processed studies than industry standard timelines and reducing certain study completion times from months to weeks through AI models that extract and analyze data from biopharma research papers, patents, and regulatory documents at scale.
AI quality assurance with insurance-backed warranties from Swiss Re and Greenlight Re; EU AI Act compliance assessments backed by YC and reinsurance partners for high-risk AI deployments.
About
Armilla AI is a third-party AI quality assurance and warranty company that evaluates AI models for organizations deploying AI in regulated or high-stakes contexts — assessing models against EU AI Act and NIST AI Risk Management Framework requirements for risks including bias, hallucination, robustness failures, and adversarial vulnerabilities, then providing performance guarantees backed by insurance coverage from reinsurers Swiss Re, Greenlight Re, and Chaucer. Founded in Toronto, Canada, Armilla raised $6.81 million total including a C$4.5 million seed round in February 2024 from Mistral Venture Partners, MS&AD Ventures, Y Combinator, and its reinsurance partners.\n\nArmilla's model is unique in the AI governance market — rather than just providing compliance reports, Armilla backs its assessments with insurance warranty products. An enterprise deploying a third-party AI model can purchase an Armilla warranty that pays out if the model performs differently than assessed (fails on bias, accuracy, or robustness metrics), transferring AI performance risk to insurance markets that can price and distribute it. This insurance mechanism creates financial accountability for AI quality claims that audit reports alone don't provide.\n\nIn 2025, Armilla competes in the AI governance, risk, and compliance market with Credo AI, Arthur AI, and AI audit firms for enterprise AI risk assessment and compliance tools. The EU AI Act, fully applicable by August 2025 for high-risk AI systems, is driving enterprise compliance urgency — companies deploying AI in hiring, credit scoring, healthcare, and other regulated contexts need third-party conformity assessments. Armilla's insurance-backed warranty differentiates its offering from pure advisory competitors. The reinsurer backing (Swiss Re, Greenlight Re, Chaucer) provides both capital credibility and distribution through insurance broker channels. The 2025 strategy focuses on growing EU AI Act compliance assessments and expanding the warranty product coverage to more AI deployment use cases.
AI Visibility Head-to-Head
Also Compare
Delineate vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.